Across the recent three months, 25 analysts have shared their insights on Eli Lilly and Co LLY, expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 18 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 4 | 9 | 0 | 0 | 0 |
| 2M Ago | 1 | 4 | 0 | 0 | 0 |
| 3M Ago | 2 | 4 | 0 | 0 | 0 |
Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate of $840.00. This current average has increased by 4.14% from the previous average price target of $893.92.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly and Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Kerry Holford | Berenberg | Raises | Buy | $1000.00 | $850.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $1000.00 | $900.00 |
| Carter Gould | Barclays | Raises | Overweight | $1025.00 | $913.00 |
| Terence Flynn | Morgan Stanley | Maintains | Overweight | $1023.00 | $1023.00 |
| Evan Seigerman | BMO Capital | Maintains | Outperform | $1001.00 | $1001.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $1000.00 | $892.00 |
| Akash Tewari | Jefferies | Raises | Buy | $1015.00 | $994.00 |
| Geoff Meacham | B of A Securities | Maintains | Buy | $1000.00 | $1000.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Akash Tewari | Jefferies | Raises | Buy | $957.00 | $925.00 |
| David Toung | Argus Research | Raises | Buy | $840.00 | $770.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $1001.00 | $900.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $900.00 | $850.00 |
| Louise Chen | Cantor Fitzgerald | Raises | Overweight | $885.00 | $815.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $892.00 | $850.00 |
| Louise Chen | Cantor Fitzgerald | Raises | Overweight | $885.00 | $815.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Eli Lilly and Co. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eli Lilly and Co compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Eli Lilly and Co's stock. This analysis reveals shifts in analysts' expectations over time.
For valuable insights into Eli Lilly and Co's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Eli Lilly and Co analyst ratings.
Discovering Eli Lilly and Co: A Closer Look
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Breaking Down Eli Lilly and Co's Financial Performance
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Eli Lilly and Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.98% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Eli Lilly and Co's net margin is impressive, surpassing industry averages. With a net margin of 25.58%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Eli Lilly and Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 19.02%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Eli Lilly and Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.51%, the company showcases efficient use of assets and strong financial health.
Debt Management: Eli Lilly and Co's debt-to-equity ratio stands notably higher than the industry average, reaching 2.05. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
